Drug intelligence / Profile preview

OV815

Development stage: Preclinical
Lead developer: Ovid Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

OV815 is a preclinical gene-modulation therapy under development by Ovid Therapeutics. It is focused on the kinesin family of proteins and initially targets **KIF1A**, a motor protein essential for axonal transport in neurons. The drug is being developed as a potential genetic therapy for KIF1A-associated neurological disorder and possibly other diseases involving kinesin dysfunction. OV815 represents a novel therapeutic approach for rare genetic disorders affecting neural transport mechanisms. The program is being advanced in collaboration with the Genomics Center at Columbia University[2][5][7].

Targets

KIF1A (Kinesin family member 1A)

Beyond the preview

Go deeper on OV815.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV815.

Explore the full profile